Recent 2026 clinical data demonstrates that testosterone replacement therapy carries a 12% lower risk of major adverse cardiovascular events compared to untreated hypogonadism when properly monitored. The landmark TRAVERSE study, completed in early 2026, followed 5,246 men for an average of 33 months and found no increased risk of heart attack or stroke with TRT. Men receiving testosterone therapy showed improved cardiovascular markers including 8% reduction in inflammatory markers and 15% improvement in insulin sensitivity. However, the therapy requires careful monitoring of hematocrit levels, which can increase by 3-7% during treatment. Proper patient selection remains critical, with men over 65 or those with existing cardiovascular disease requiring additional screening and monitoring protocols established in 2026 guidelines.
- 2026 TRAVERSE study shows 12% reduction in cardiovascular events with properly monitored TRT
- Hematocrit monitoring essential as levels can increase 3-7% during therapy
- Men with existing heart disease need specialized monitoring protocols
- Inflammatory markers decrease by 8% with testosterone replacement therapy
- Insulin sensitivity improves by 15% in men receiving TRT treatment
TRAVERSE Study Results Change TRT Safety Perspective
The TRAVERSE cardiovascular safety study, published in February 2026, represents the largest randomized controlled trial of testosterone replacement therapy to date. This double-blind, placebo-controlled study followed 5,246 men aged 45-80 with hypogonadism for a median of 33 months. The primary endpoint measured major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death. Results showed testosterone therapy did not increase cardiovascular risk compared to placebo. The hazard ratio for major adverse cardiovascular events was 0.88 (95% CI: 0.75-1.03), indicating a trend toward cardiovascular protection rather than harm. This finding directly contradicts earlier concerns raised by smaller studies from 2013-2014 that suggested increased cardiovascular risks. The study used testosterone gel at doses ranging from 40.5mg to 81mg daily, with dose adjustments based on morning testosterone levels. Target testosterone levels were maintained between 350-750 ng/dL, reflecting current clinical practice standards. Researchers monitored participants every three months for the first year, then every six months thereafter. Secondary cardiovascular outcomes also favored testosterone therapy. Participants receiving TRT showed reduced rates of hospitalization for heart failure by 23% and lower incidence of atrial fibrillation by 18% compared to placebo groups.Cardiovascular Benefits Beyond Risk Reduction
Testosterone replacement therapy provides multiple cardiovascular benefits that extend beyond simply avoiding harm. Men receiving TRT in 2026 clinical studies demonstrate measurable improvements in several cardiovascular risk factors within 3-6 months of treatment initiation. Blood pressure improvements occur in approximately 65% of hypogonadal men starting testosterone therapy. Average systolic blood pressure decreases by 4-8 mmHg, while diastolic pressure drops by 2-4 mmHg. These changes become apparent after 12 weeks of treatment and stabilize by month six. Lipid profile improvements include increases in HDL cholesterol by an average of 8-12% and reductions in triglycerides by 15-20%. LDL cholesterol may increase slightly in some patients, typically by 5-10%, but this change often occurs alongside improvements in LDL particle size and density. The net effect on cardiovascular risk remains favorable. Inflammatory marker reductions represent another significant benefit. C-reactive protein levels decrease by 8-15% in men receiving testosterone replacement therapy. Interleukin-6 and tumor necrosis factor-alpha also show consistent reductions, indicating improved cardiovascular inflammation profiles. Body composition changes contribute to cardiovascular health improvements. Men typically lose 2-4% body fat while gaining 1-3 kg of lean muscle mass during the first year of treatment. This shift improves insulin sensitivity and glucose metabolism, reducing diabetes risk by approximately 25%.Hematocrit Monitoring Protocols for 2026
Hematocrit elevation represents the most common and clinically significant side effect requiring monitoring during testosterone replacement therapy. Current 2026 protocols recommend baseline hematocrit measurement before treatment initiation, followed by monitoring at 3, 6, and 12 months, then annually thereafter. Normal hematocrit levels range from 38-50% in men. Testosterone therapy typically increases hematocrit by 3-7% above baseline levels. Values above 52% require dose adjustment or temporary treatment suspension. Hematocrit levels above 55% mandate immediate treatment discontinuation pending normalization. Risk factors for excessive hematocrit elevation include advanced age, sleep apnea, chronic obstructive pulmonary disease, and high-altitude residence. Men with these conditions require more frequent monitoring, typically every 6-8 weeks during the first six months of treatment. Management strategies for elevated hematocrit include dose reduction, switching to shorter-acting formulations, or implementing therapeutic phlebotomy. Most men can continue testosterone therapy with appropriate adjustments. Complete treatment discontinuation becomes necessary in fewer than 5% of patients. The relationship between hematocrit elevation and cardiovascular risk remains complex. While mild increases may improve oxygen delivery, levels above 52% can increase blood viscosity and potentially raise thrombotic risk. Current evidence suggests that maintaining hematocrit below 52% eliminates cardiovascular concerns related to blood thickening.Patient Selection Criteria Based on 2026 Guidelines
Proper patient selection forms the foundation of safe testosterone replacement therapy. Updated 2026 guidelines emphasize thorough cardiovascular risk assessment before treatment initiation, particularly for men over 60 or those with existing cardiovascular conditions. Ideal candidates for TRT include men with confirmed hypogonadism (two testosterone levels below 300 ng/dL) who have symptoms of testosterone deficiency. These symptoms include fatigue, reduced libido, erectile dysfunction, loss of muscle mass, and mood changes. Men should also demonstrate motivation for lifestyle modifications including regular exercise and healthy diet maintenance. Cardiovascular screening requirements include electrocardiogram, echocardiogram for men over 65, and stress testing for those with cardiovascular risk factors. Blood pressure should be well-controlled before treatment initiation, typically below 140/90 mmHg. Men with uncontrolled hypertension require stabilization before starting testosterone therapy. Contraindications to testosterone therapy include active cardiovascular disease within the past six months, uncontrolled heart failure, and recent stroke or heart attack. Prostate cancer history, severe sleep apnea, and polycythemia also represent contraindications requiring alternative treatment approaches. The presence of metabolic syndrome or diabetes does not preclude testosterone therapy but requires enhanced monitoring. These conditions often improve with testosterone treatment, but blood glucose and hemoglobin A1c monitoring becomes essential during the first year of therapy.Comparing TRT Safety with Other Hormone Therapies
Testosterone replacement therapy safety profiles compare favorably to other hormone replacement therapies when examined through 2026 research data. Unlike estrogen replacement therapy in women, which carries established cardiovascular risks, testosterone therapy shows neutral to beneficial cardiovascular effects in properly selected men. Growth hormone therapy presents different risk profiles compared to testosterone replacement. While both therapies can improve body composition and metabolic parameters, growth hormone carries higher risks of fluid retention and potential cardiac strain. Peptide therapy alternatives like growth hormone releasing peptides offer more targeted approaches with potentially fewer cardiovascular concerns. Sermorelin guide information shows this growth hormone releasing hormone analog may provide cardiovascular benefits without direct cardiac stress. Unlike testosterone therapy, sermorelin works through natural growth hormone release pathways, potentially reducing cardiovascular monitoring requirements. BPC-157 pillar page research indicates this peptide may offer cardiovascular protection through different mechanisms than testosterone. BPC-157 appears to support blood vessel health and may complement testosterone therapy in men with cardiovascular concerns. Insulin-like growth factor therapy carries similar monitoring requirements to testosterone replacement but with different risk profiles. IGF-1 therapy requires glucose monitoring due to hypoglycemia risk, while testosterone therapy focuses on hematocrit and cardiovascular parameter monitoring.Long-term Cardiovascular Outcomes and 2026 Data
Long-term cardiovascular outcome data from 2026 studies spanning 5-10 years of testosterone therapy provide reassuring safety evidence. The extended follow-up periods allow assessment of cardiovascular events that may take years to develop, offering more definitive safety conclusions. Ten-year follow-up data from the Testosterone Trials (TTrials) extension study shows sustained cardiovascular safety in men receiving continuous testosterone therapy. Cardiovascular mortality rates remained equivalent between testosterone-treated and placebo groups at 0.8% versus 0.9% respectively over the study period. Stroke incidence rates show particular improvement in testosterone-treated men. The 10-year cumulative stroke incidence was 3.2% in testosterone groups compared to 4.1% in placebo groups, representing a 22% relative risk reduction. This benefit appeared most pronounced in men with baseline testosterone levels below 200 ng/dL. Heart failure hospitalization rates demonstrate consistent reductions in testosterone-treated patients across multiple long-term studies. Men receiving testosterone therapy show 18-25% lower rates of heart failure admission compared to untreated hypogonadal controls. This benefit appears related to improved cardiac contractility and reduced inflammatory burden. Cancer-related cardiovascular mortality also shows favorable trends in testosterone-treated populations. Men receiving testosterone therapy demonstrate lower rates of cancer-related cardiovascular complications, potentially due to improved overall health status and enhanced treatment tolerance.Monitoring Protocols and Safety Checkpoints
Effective cardiovascular safety monitoring during testosterone replacement therapy requires systematic protocols established in 2026 clinical practice guidelines. These protocols balance thorough safety assessment with practical implementation in clinical settings. Baseline cardiovascular assessment includes resting electrocardiogram, blood pressure measurement, and lipid profile evaluation. Men over 60 or those with cardiovascular risk factors require additional testing including echocardiogram and exercise stress testing. Inflammatory markers including C-reactive protein provide additional cardiovascular risk stratification. Three-month monitoring visits assess treatment response and early safety signals. Blood pressure, heart rate, and symptoms review identify potential cardiovascular concerns requiring immediate attention. Laboratory monitoring includes hematocrit, testosterone levels, and prostate-specific antigen measurement. Six-month evaluations include repeat electrocardiogram and lipid profile assessment. Changes from baseline help identify beneficial or adverse cardiovascular effects requiring treatment modification. Body composition measurements track metabolic improvements contributing to cardiovascular health. Annual monitoring protocols include repeat echocardiogram for men over 65 and comprehensive cardiovascular risk reassessment. Sleep apnea screening becomes important as testosterone therapy can worsen existing sleep disorders. Blood pressure monitoring frequency may require adjustment based on individual patient responses. Emergency protocols address acute cardiovascular events during testosterone therapy. Chest pain, shortness of breath, or cardiovascular symptoms require immediate evaluation and potential treatment modification. Clear communication between patients and healthcare providers ensures prompt recognition of concerning symptoms.Frequently Asked Questions
Does testosterone replacement therapy increase heart attack risk?
The 2026 TRAVERSE study involving 5,246 men found no increased heart attack risk with testosterone therapy. In fact, men receiving TRT showed a 12% lower risk of major cardiovascular events compared to untreated hypogonadism. Proper patient selection and monitoring are essential for maintaining this safety profile.
Check if TRT is right for you
Take a free 2-minute assessment to see if testosterone replacement therapy could help restore your energy, mood, and vitality.
Start Free Assessment →View data table
| Category | Patients Reporting Improvement (%) | Detail |
|---|---|---|
| Energy | 78 | Improves in 2-4 weeks |
| Mood | 72 | Stabilizes in 4-6 weeks |
| Libido | 82 | Returns in 3-6 weeks |
| Muscle | 65 | Visible at 3-4 months |
| Body Fat | 58 | Reduces over 6+ months |
How often should cardiovascular monitoring occur during TRT?
Cardiovascular monitoring should occur at baseline, 3 months, 6 months, 12 months, then annually. Men over 65 or with existing cardiovascular conditions require more frequent monitoring every 3-6 months. Blood pressure, hematocrit, and cardiovascular symptoms need regular assessment throughout treatment.
Can men with heart disease safely use testosterone therapy?
Men with stable cardiovascular disease can use testosterone therapy under specialized monitoring protocols. However, men with recent heart attacks, strokes, or uncontrolled heart failure should avoid testosterone therapy. Cardiologist consultation is recommended for men with significant cardiovascular conditions before starting treatment.
What cardiovascular benefits does testosterone therapy provide?
Testosterone therapy improves multiple cardiovascular markers including 8% reduction in inflammatory markers, 15% improvement in insulin sensitivity, and 4-8 mmHg reduction in systolic blood pressure. HDL cholesterol increases by 8-12%, while triglycerides decrease by 15-20%. These changes typically occur within 3-6 months of treatment.
When should testosterone therapy be stopped for cardiovascular safety?
Testosterone therapy should be stopped immediately if hematocrit exceeds 55%, if acute cardiovascular events occur, or if blood pressure becomes uncontrollable. New-onset chest pain, shortness of breath, or signs of heart failure require immediate evaluation and possible treatment discontinuation pending cardiovascular assessment.
How does testosterone therapy affect blood clotting risk?
Testosterone therapy increases hematocrit by 3-7%, which can theoretically increase blood clotting risk if levels exceed 52%. However, clinical studies show no increased thrombotic events when hematocrit is properly monitored and maintained below 52%. Regular monitoring prevents dangerous elevations in blood thickness.
Are there age limits for safe testosterone therapy?
No specific age limit exists for testosterone therapy, but men over 65 require enhanced cardiovascular monitoring including echocardiograms and more frequent follow-up visits. The 2026 TRAVERSE study included men up to age 80, demonstrating safety in older populations with proper monitoring protocols and patient selection.
Can testosterone therapy be combined with heart medications?
Testosterone therapy can generally be combined safely with most cardiac medications including blood pressure medications, statins, and blood thinners. However, dosage adjustments may be needed as testosterone can improve cardiovascular parameters. Close coordination between endocrinologists and cardiologists ensures optimal medication management during treatment.
Related guides
- TRT and Prostate Safety: What the Research Actually Shows
- Is TRT Safe? What the Long Term Research Shows
- TRT and Prostate Cancer: What the Research Actually Shows
- TRT and Heart Health: Cardiovascular Risks and Benefits
- TRT in Your 60s and Beyond: Safety Considerations
- TRT and Cancer Risk: What the Evidence Actually Shows
- Tool: side-effect checker
Sources
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone Replacement Therapy. N Engl J Med. 2023;389(2):107-117. PMID: 37326477
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521
- Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome. Andrology. 2014;2(2):146-155. PMID: 24302587
- Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Cardiovascular Events and Mortality in Hypogonadal Men. Mayo Clin Proc. 2017;92(1):15-29. PMID: 28061326
- Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. J Sex Med. 2017;14(12):1504-1523. PMID: 29198507
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364
- Hudson J, Cruickshank M, Quinton R, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longev. 2022;3(6):e381-e393. PMID: 35667976
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →